Sign In
Buy NPCE
$12.89
-0.86 (-6.25%)
At Close: Jul 31, 2026
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
01:03am, Wednesday, 29'th Jul 2026
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
06:07pm, Tuesday, 28'th Jul 2026
NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket approval supplement seeking to expand the RNS System indication to patients with medication-resistant id
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
04:01pm, Tuesday, 28'th Jul 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S.
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
11:25am, Wednesday, 15'th Jul 2026
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
10:55am, Monday, 15'th Jun 2026
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 11'th Jun 2026
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
11:41am, Wednesday, 10'th Jun 2026
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
12:51pm, Tuesday, 02'nd Jun 2026
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
08:00am, Friday, 29'th May 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
12:00pm, Wednesday, 27'th May 2026
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
NPCE Explains How NeuroPace's RNS System Makes Money
11:46am, Wednesday, 27'th May 2026
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
11:36am, Wednesday, 27'th May 2026
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
01:25pm, Wednesday, 13'th May 2026
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
10:10pm, Tuesday, 12'th May 2026
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
